See more : Reit 1 Ltd (RIT1.TA) Income Statement Analysis – Financial Results
Complete financial analysis of AgeX Therapeutics, Inc. (AGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AgeX Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Sijin Intelligent Forming Machinery Co., Ltd. (003025.SZ) Income Statement Analysis – Financial Results
- Xali Gold Corp. (XGC.V) Income Statement Analysis – Financial Results
- Plascar Participações Industriais S.A. (PLAS3.SA) Income Statement Analysis – Financial Results
- Tayca Corporation (4027.T) Income Statement Analysis – Financial Results
- GDI Property Group (GDI.AX) Income Statement Analysis – Financial Results
AgeX Therapeutics, Inc. (AGE)
About AgeX Therapeutics, Inc.
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 142.00K | 34.00K | 144.00K | 1.87M | 1.73M | 1.40M | 1.40M |
| Cost of Revenue | 171.00K | 13.00K | 19.00K | 158.00K | 244.00K | 364.00K | 168.00K |
| Gross Profit | -29.00K | 21.00K | 125.00K | 1.71M | 1.48M | 1.03M | 1.24M |
| Gross Profit Ratio | -20.42% | 61.76% | 86.81% | 91.54% | 85.88% | 73.93% | 88.03% |
| Research & Development | 603.00K | 1.03M | 1.46M | 4.98M | 5.90M | 6.63M | 5.78M |
| General & Administrative | 9.33M | 5.97M | 6.71M | 7.40M | 8.14M | 5.65M | 3.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.33M | 5.97M | 6.71M | 7.40M | 8.14M | 5.65M | 3.87M |
| Other Expenses | 11.00K | 13.00K | 448.00K | 44.00K | 294.00K | 183.00K | 38.00K |
| Operating Expenses | 9.93M | 7.00M | 8.16M | 12.38M | 14.04M | 12.28M | 9.65M |
| Cost & Expenses | 10.10M | 7.01M | 8.18M | 12.54M | 14.29M | 12.64M | 9.82M |
| Interest Income | 0.00 | 3.34M | 1.10M | 404.00K | 29.00K | 0.00 | 0.00 |
| Interest Expense | 4.90M | 3.34M | 1.10M | 0.00 | 0.00 | 116.00K | 0.00 |
| Depreciation & Amortization | 131.00K | 145.00K | 579.00K | 1.68M | 951.00K | 535.00K | 682.00K |
| EBITDA | -9.83M | -6.98M | -7.93M | -9.15M | -11.61M | -10.71M | -9.49M |
| EBITDA Ratio | -6,921.83% | -20,088.24% | -5,180.56% | -481.21% | -671.76% | -767.19% | -675.85% |
| Operating Income | -9.96M | -6.98M | -8.04M | -10.67M | -12.56M | -11.25M | -6.66M |
| Operating Income Ratio | -7,014.08% | -20,514.71% | -5,582.64% | -571.25% | -726.79% | -805.52% | -474.57% |
| Total Other Income/Expenses | -4.85M | -3.55M | -649.00K | 272.00K | 323.00K | 3.51M | 1.78M |
| Income Before Tax | -14.81M | -10.52M | -8.58M | -11.13M | -12.24M | -7.73M | -6.64M |
| Income Before Tax Ratio | -10,430.28% | -30,947.06% | -5,959.72% | -595.61% | -708.10% | -553.80% | -472.72% |
| Income Tax Expense | -8.00K | 152.00K | 1.64M | -150.00K | 148.00K | 3.51M | -1.80M |
| Net Income | -14.80M | -10.67M | -10.22M | -10.98M | -12.38M | -7.50M | -6.58M |
| Net Income Ratio | -10,424.65% | -31,394.12% | -7,097.22% | -587.58% | -716.67% | -537.39% | -468.66% |
| EPS | -13.72 | -9.89 | -9.49 | -10.25 | -11.69 | -7.56 | -6.46 |
| EPS Diluted | -13.72 | -9.89 | -9.49 | -10.25 | -11.69 | -7.56 | -6.46 |
| Weighted Avg Shares Out | 1.08M | 1.08M | 1.08M | 1.07M | 1.06M | 992.72K | 1.02M |
| Weighted Avg Shares Out (Dil) | 1.08M | 1.08M | 1.08M | 1.07M | 1.06M | 992.72K | 1.02M |
AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer
AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX's Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity
AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only
Where Do Hedge Funds Stand On AgeX Therapeutics, Inc. (AGE)?
Mid-Day Market Update: Gold Gains 2%; ShiftPixy Shares Plunge
Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Consumer Portfolio Services Shares Spike Higher
Sushant Singh Rajput death case: Siddharth Pithani arrives at ED office
ED to question Sushant Singh Rajput's roommate Siddharth Pithani today
Sushant Singh Rajput Death Case LIVE Updates: Siddharth Pithani to be investigated by ED today
Sushant Singh Rajput case: ED interrogates Rhea Chakraborty but the actress remains evasive - Times of India
Source: https://incomestatements.info
Category: Stock Reports